WuXi Biologics concludes acquisition of a drug product plant from Bayer

With a team led by Dirk W. Kolvenbach, the globally operating WuXi Biologics group acquired a sterile filling and freeze-drying plant from Bayer AG. The transaction has now been successfully concluded. The plant is designed for filling and freeze-drying the blood clotting agent Kovaltry®. The plant is operated on the Chempark site in Leverkusen.
 
Under the asset purchase agreement signed in January, WuXi Biologics took over operations of the plant, purchased the associated equipment and signed a long-term lease contract for the building. Equipped with a state-of-the-art filling facility for pharmaceutical products, the plant will offer sterile filling and freeze-drying of up to 10 million vials per year.
 
“We are excited to enter into this significant agreement with Bayer and to develop our second site in Europe,” said Dr. Chris Chen, CEO of WuXi Biologics. “This new facility in Germany will allow us to better serve our global customers by implementing the unique manufacturing paradigm of ‘Global Dual Sourcing’ through our robust and premier-quality supply chain network. We will continue to enable our global partners to develop and manufacture biologics to benefit patients worldwide.”
 
WuXi Biologics is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. To support the fight against COVID-19, WuXi Biologics has donated more than 1,600 masks to medical institutions in Leverkusen.

Counsel to WuXi Biologics
Heuking Kühn Lüer Wojtek: 
Dirk W. Kolvenbach (Lead), Düsseldorf
Michael Pauli, LL.M. (Corporate), Cologne
Wolfram Meven,
Jörn Matuszewski (both Tax), both Düsseldorf
Dr. Rainer Velte (Antitrust), Düsseldorf
Fabian Gerstner, LL.M.
Bettina Neheider (both Construction), both Munich
Christoph Nöhles, LL.M. 
Mathis Dick, LL.M. (both Real Estate), both Düsseldorf
Dr. Bodo Dehne (Investment Control)
Dr. Tobias Plath, LL.M. (Insurance), Düsseldorf
Torsten Groß, LL.M. (Employment), Düsseldorf
Sarah Radon, LL.M. (Commercial), Düsseldorf
 
Counsel to Bayer
Redeker Sellner Dahs:
Dr. Markus Dierksmeier (Corporate), 
Bartholomäus Aengenvoort 
Alexander Leidig (both Real Estate), all Bonn